ASTH Stock Forecast & Price Target

Astrana Health is well-positioned in the growing value-based care market, with diverse revenue streams and a focus on cost management through AI technology. Key factors to watch include their RAF scores and potential challenges with Part B drugs and Medicaid disenrollment, but the overall outlook is positive with a Buy rating and potential for growth. Overall, Astrana Health's strong position in the value-based care market, diverse revenue streams, and cost management strategies make it a solid investment with potential for growth in the future. However, investors should keep an eye on key metrics such as RAF scores and potential challenges that could impact the company's performance. With a Buy rating, Astrana is a promising stock choice for those looking to invest in the healthcare sector.

Astrana Health is a strong integrated population health management company that is successfully reducing costs and improving care quality in the current healthcare industry, and is strategically focused on senior patients and chronic conditions. The company's ACO REACH program has shown significant gross savings and increasing quality scores, while its partnership with Aledade bodes well for future success. Additionally, Astrana's acquisition of Prospect Medical, with a majority of its revenue coming from outpatient sites, aligns with the company's value-based care efforts and has strong future growth potential. However, Astrana also faces typical risks associated with healthcare companies, including a changing market, regulatory and political uncertainties, and potential upfront costs. All in all, Astrana's strong fundamentals and promising prospects make it a Buy-rated stock with a price target of $50, representing a 9.2x multiple of 2027E EBITDA.